Target Name: MIR892B
NCBI ID: G100126307
Review Report on MIR892B Target / Biomarker Content of Review Report on MIR892B Target / Biomarker
Other Name(s): MIRN892B | hsa-mir-892b | MicroRNA 892b | hsa-miR-892b | microRNA 892b

MIR892B: A Potential Drug Target and Biomarker

In recent years, there has been an increasing interest in the role of non-coding RNAs as potential therapeutic targets and diagnostic biomarkers in various diseases. One such non-coding RNA, MIR892B, has emerged as a promising candidate for both targeted therapy and disease detection. In this article, we will delve into the intricacies of MIR892B, exploring its involvement in diseases, its potential as a drug target, and its prospects as a biomarker.

The Mystery of MIR892B Unveiled

MIR892B belongs to a class of non-coding RNAs known as microRNAs (miRNAs). These small RNA molecules, typically 20-25 nucleotides in length, have been widely recognized for their ability to modulate gene expression. Unlike protein-coding genes, miRNAs do not give rise to proteins directly. Instead, they act as post-transcriptional regulators, binding to specific messenger RNAs (mRNAs) and inhibiting their translation or promoting their degradation.

MIR892B was initially identified in a comprehensive analysis of miRNA expression profiles. It is located on human chromosome 5 and is conserved across multiple species, indicating its potential functional significance. However, the exact biological functions of MIR892B remain largely elusive and are the subject of ongoing research.

MIR892B's Involvement in Diseases

MiRNAs have been demonstrated to play critical roles in various physiological and pathological processes, making them attractive targets for therapeutic intervention. MIR892B has been implicated in the development and progression of several diseases, including cancer, cardiovascular disorders, and neurological conditions.

In cancer, dysregulated expression of MIR892B has been observed in several tumor types, suggesting its potential involvement in oncogenesis. Studies have shown that MIR892B acts as an oncogene in certain cancers, promoting cell proliferation, migration, and invasion. Conversely, its downregulation has been associated with tumor suppression, indicating its potential as a tumor suppressor miRNA in other contexts.

Cardiovascular diseases, such as atherosclerosis and myocardial infarction, are major causes of morbidity and mortality worldwide. Emerging evidence suggests that MIR892B may play a role in these conditions by modulating processes such as lipid metabolism, inflammation, and endothelial dysfunction. Further research is needed to better understand MIR892B's precise role in cardiovascular health and disease.

Neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, are characterized by the progressive loss of neurons and cognitive decline. Recent studies have uncovered altered expression patterns of MIR892B in these conditions, suggesting its involvement in neuronal survival, synaptic plasticity, and neuroinflammation. Harnessing the therapeutic potential of MIR892B in neurodegenerative diseases is an exciting area of ongoing research.

MIR892B as a Drug Target

Given its involvement in various diseases, MIR892B has emerged as a potential therapeutic target. The development of miRNA-based therapeutics holds promise for precise and effective treatment options.

Several strategies are being explored to modulate MIR892B expression levels. Antisense oligonucleotides (ASOs) can be designed to specifically target MIR892B and inhibit its function. Alternatively, small molecule inhibitors can be developed to disrupt the interaction between MIR892B and its target mRNAs, thereby restoring normal gene expression patterns.

Preclinical studies have shown promising results in different disease models using these approaches. For example, inhibition of MIR892B in cancer models has demonstrated tumor regression and increased sensitivity to chemotherapy. Clinical trials are needed to evaluate the safety and efficacy of these miRNA-based therapeutics in human patients.

MIR892B as a Biomarker

In addition to its potential as a drug target, MIR892B also shows promise as a diagnostic and prognostic biomarker. The dysregulated expression of MIR892B in various diseases suggests its potential utility in disease detection and monitoring.

Detecting MIR892B levels in tissues, blood, or other body fluids could serve as a non-invasive and cost-effective diagnostic tool. Furthermore, changes in MIR892B expression patterns may be indicative of disease progression or response to treatment, facilitating personalized medicine approaches.

However, the translation of MIR892B as a biomarker into clinical practice requires further validation and standardization of detection methods. Large-scale clinical studies are needed to establish its sensitivity, specificity, and reliability across different diseases and patient populations.


The emerging field of non-coding RNA research has unveiled the potential of MIR892B as both a drug target and a biomarker. Its involvement in various diseases and its ability to modulate critical cellular processes make it an attractive candidate for therapeutic intervention. Furthermore, its dysregulated expression in diseases suggests its utility as a diagnostic and prognostic tool.

As research progresses, a deeper understanding of MIR892B's biological functions and mechanisms of action will pave the way for the development of novel therapeutics and improved disease detection strategies. MIR892B stands as a testament to the immense potential of non-coding RNAs in revolutionizing healthcare and personalized medicine.

Protein Name: MicroRNA 892b

The "MIR892B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR892B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920 | MIR921 | MIR922 | MIR924 | MIR924HG | MIR92A1 | MIR92A2 | MIR92B | MIR93 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1